Christoph Gaul

Basel, BS 4002, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Evolution of Novartis' Small Molecule Screening Deck Design.

Evolution of Novartis' Small Molecule Screening Deck Design.

Journal: Journal of medicinal chemistry

Published: November 03, 2020

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.

Journal: Blood

Published: April 01, 2020

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

Journal: ACS medicinal chemistry letters

Published: October 01, 2019

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.

Journal: Oncotarget

Published: June 17, 2019

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Journal: MedChemComm

Published: April 27, 2017

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Journal: ACS medicinal chemistry letters

Published: December 23, 2016

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

Journal: ACS medicinal chemistry letters

Published: April 21, 2016

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Journal: ACS medicinal chemistry letters

Published: April 21, 2016

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Journal: Cancer cell

Published: November 03, 2014

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Journal: Cancer cell

Published: November 03, 2014

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Journal: Cancer discovery

Published: June 12, 2012

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Journal: The Journal of experimental medicine

Published: January 25, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026